Pfizer reported positive Phase 3 results showing that the combination of TALZENNA and XTANDI significantly improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer carrying HRR gene mutations . The study met its primary endpoint with a clinically meaningful reduction in the risk of disease progression or death compared to standard treatment.

The treatment demonstrated consistent benefits across both BRCA and non-BRCA patient groups, while interim data also संकेत a strong trend toward improved overall survival. Additional secondary endpoints, including response rates and time to PSA progression, also showed favorable outcomes.

Pfizer plans to engage with global regulators to potentially expand the indication of TALZENNA to earlier-stage prostate cancer, highlighting the combination’s potential to shift treatment earlier in the disease course and reinforce the company’s precision oncology strategy.
Business Wire